These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31090588)

  • 1. The evolving role of anabolic therapy in the treatment of osteoporosis.
    Cosman F
    Curr Opin Rheumatol; 2019 Jul; 31(4):376-380. PubMed ID: 31090588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture.
    Cosman F
    Endocr Pract; 2020 Jul; 26(7):777-786. PubMed ID: 33471647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO).
    Silva BC; Madeira M; d'Alva CB; Maeda SS; de Holanda NCP; Ohe MN; Szejnfeld V; Zerbini CAF; de Paula FJA; Bandeira F
    Arch Endocrinol Metab; 2022 Nov; 66(5):591-603. PubMed ID: 36191263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
    Cosman F; Dempster DW
    Curr Osteoporos Rep; 2021 Apr; 19(2):189-205. PubMed ID: 33635520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the optimal use of bone forming agents in osteoporosis.
    Veronese N; Briot K; Guañabens N; Albergaria BH; Alokail M; Al-Daghri N; Bemden AB; Bruyère O; Burlet N; Cooper C; Curtis EM; Ebeling PR; Halbout P; Hesse E; Hiligsmann M; Camargos BM; Harvey NC; Perez AD; Radermecker RP; Reginster JY; Rizzoli R; Siggelkow H; Cortet B; Brandi ML
    Aging Clin Exp Res; 2024 Aug; 36(1):167. PubMed ID: 39120740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of osteoporosis.
    Palacios S
    Climacteric; 2022 Feb; 25(1):43-49. PubMed ID: 34382489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of anabolic agents in the treatment of osteoporosis: a clinical update.
    Inderjeeth CA; Inderjeeth DC
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):157-163. PubMed ID: 38752851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for osteoporosis.
    Feurer E; Chapurlat R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):385-95. PubMed ID: 24995794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients at very high risk of osteoporotic fractures through sequential treatments.
    Curtis EM; Reginster JY; Al-Daghri N; Biver E; Brandi ML; Cavalier E; Hadji P; Halbout P; Harvey NC; Hiligsmann M; Javaid MK; Kanis JA; Kaufman JM; Lamy O; Matijevic R; Perez AD; Radermecker RP; Rosa MM; Thomas T; Thomasius F; Vlaskovska M; Rizzoli R; Cooper C
    Aging Clin Exp Res; 2022 Apr; 34(4):695-714. PubMed ID: 35332506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoanabolic Agents for Osteoporosis.
    Haas AV; LeBoff MS
    J Endocr Soc; 2018 Aug; 2(8):922-932. PubMed ID: 30087947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of bone fragility in patients with diabetes: antiresorptive versus anabolic?
    Shah M; Appuswamy AV; Rao SD; Dhaliwal R
    Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):377-382. PubMed ID: 34010225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
    Bilezikian JP; Rubin MR
    Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging anabolic agents in the treatment of osteoporosis.
    Lovato C; Lewiecki EM
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):247-257. PubMed ID: 28756709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report.
    McGreevy JL; Kane MP; Busch RS; Bakst G; ElDeiry S
    J Am Pharm Assoc (2003); 2019; 59(4):593-597. PubMed ID: 31101442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anabolic treatments for osteoporosis in postmenopausal women.
    Hassan N; Gregson CL; Tobias JH
    Fac Rev; 2021; 10():44. PubMed ID: 34131654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.